Wende Hutton

General Partner, Canaan Partners Health Care Venture Capital

[Wende Hutton @WendeHutton]

Big Pharma has a model to make a profit and save lives. So, whats the hold-up? - Blog - Business in Global Society - Harvard Business School https://t.co/KL8qlvRIza

[OncoResponse @OncoResponse]

CEO @CliffordStocks and CMO Bob Lechleider enjoying their time in Chicago at the @ASCO annual meeting! #ASCO23 #EliteCancerResponders

[Wende Hutton @WendeHutton]

@canaanpartners Looking ahead to helping the Antiva team bring a much-needed medicine to patients who suffer from hrHPV infections.

[OncoResponse @OncoResponse]

AACR 2023 has begun! OncoResponse has a poster presentation on April 19th, which will publicly introduce for the first time preclinical data regarding our dual-targeting antibodies for LILRB1 and LILRB2. The poster will soon be available on our website. #EliteCancerResponders

[OncoResponse @OncoResponse]

We are now two weeks away from presenting at #AACR2023! #OncoResponse's poster will publicly introduce for the first time our preclinical data of dual-targeting antibodies for LILRB1 and LILRB2. The poster presentation will take place April 19th. @AACR #EliteCancerResponders

[Canaan @canaanpartners]

Abyrx, Inc. announced additional FDA clearances for the company's MONTAGE® Settable, Resorbable Bone Putty as both a bone void filler and cranial bone cement, which follow the highly successful clinical introduction of MONTAGE use on bleeding bone. https://t.co/hhYSOpkrRq

[Canaan @canaanpartners]

Excited to see Qlaris Bio’s co-founder and CMO, Barbara Wirostko, on @endpts Women in Biopharma ’22 list. She is helping guide the co's effort to develop innovative therapies for debilitating ophthalmic diseases. Canaan's @WendeHutton is on co's BOD. https://t.co/0ygV2CBbKF

[Canaan @canaanpartners]

Big day for PACT Pharma. Data from 1st study using #CRISPR to substitute a gene in patient’s immune cells to treat cancer presented at #SITC2022 and published in @Nature. Groundbreaking research paves way for cutting-edge therapies. https://t.co/8uKt8tBNnQ

[Canaan @canaanpartners]

Thrilled to see @HyalexOrtho appear on @BusinessInsider list of biotech startups to watch in next year. Excited to see what CEO @carl_vause and team accomplish. @WendeHutton @JuliePapanek @jesse_yeji

Read full piece with BI subscription at: https://t.co/8wkPzH1Ywz

[Canaan @canaanpartners]

Exciting to see @OncoResponse's clinical supply agreement with @Regeneron to evaluate #OR2805 in combination with Libtayo. We'll be closely watching the clinical evaluation of this combination. Canaan's @WendeHutton is on the OncoResponse board. https://t.co/0pYLHQ6CK8

[Canaan @canaanpartners]

IDEAYA announces positive interim data from P2 trial of darovasertib and crizotinib synthetic lethal combo. Provides rational for potential registration-enabling study in metastatic uveal melanoma. Canaan’s @TimShannonMD is chair of the IDEAYA board. https://t.co/TItm81Fp0l

[Wende Hutton @WendeHutton]

Congrats to Julie and the Day One team! A new day for pediatric cancer patients: Day One's share price doubles on initial data for brain tumor drug https://t.co/sNM7OoLxB6

[John Maraganore 🇺🇸🇬🇷🇺🇦 @JMaraganore]

Lots of people talking about a string of negative data in biopharma… yes, there have been some notable upsets

[Glooko @GlookoInc]

Today, we welcome Alfonso "Chito" Zulueta to the #Glooko Board of Directors. Learn about his success at @LillyPad in the pharmaceutical industry and the experience he brings as we continue to grow as a #DigitalHealth leader: https://t.co/Bh8901n8pH #BetterTogether

[Wende Hutton @WendeHutton]

Welcoming Chito Zulueto and his deep expertise in diabetes care to the Glooko board! https://t.co/Mxd5s8kiCF

[Canaan @canaanpartners]

Glooko appoints Alfonso “Chito” Zulueta, former Eli Lilly & Company Senior Executive, to Board of Directors. https://t.co/b5HMgzMDzr

[Glooko @GlookoInc]

At #ATTD2022, #Glooko will showcase its #diabetes data management and #RemotePatientMonitoring platform and industry leaders will share insights on #DigitalHealth. Experience our #ConnectedCare platform at stand 24B: https://t.co/kJzCFWv7aG #BetterTogether

[Canaan @canaanpartners]

Rondo Therapeutics has emerged from stealth mode with a bang. $67M Series A and ambitions to tackle solid tumors with next-gen #immunooncology platform. Round led by Canaan (@nkjellson) and Red Tree VC (Jon Edwards). PR from Rondo here: https://t.co/BkltggRWHi

[Glooko @GlookoInc]

Today, #Glooko announced the acquisition of DIABNEXT, a France-based company whose #DigitalHealth platform provides #diabetes #RemotePatientMonitoring and enhances physician-patient collaboration. Learn about Glooko XT, formerly DIABNEXT: https://t.co/NTruCWsRCu #BetterTogether

[Fierce Medtech @FierceMedTech]

Like @GlookoInc's own platform, the mobile app from acquisition target @DiabNext automatically takes in readings from continuous glucose monitors, insulin pumps and pens and other devices to help diabetes patients track daily health data. https://t.co/Qqm3WaC0lu